The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events.

Ennio Giulio Favalli,Gilberto Cincinelli, Sabino Germinario,Raffaele Di Taranto,Francesco Orsini,Gabriella Maioli,Martina Biggioggero,Matteo Ferrito,Roberto Caporali

Frontiers in immunology（2023）

引用 0|浏览25

暂无评分

摘要

Rigorous application of EMA indications in clinical practice could result in the exclusion of a large proportion of RA patients from treatment with JAKis. A proper quantification of the risk for MACE by dedicated tools as ERS-RA is advocated to better tailor the management of RA.

查看译文

关键词

rheumatoid arthritis, JAK inhibitors, b/tsDMARDs, safety, cardiovascular risk

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要